Current List of Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 161-163 [2010-32908]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 1 / Monday, January 3, 2011 / Notices
Dated: December 27, 2010,,
Robert Hendricks,
Director, Division of Policy and Information
Coordination.
[FR Doc. 2010–33062 Filed 12–30–10; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The concept meeting,
proposals and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the contract proposals, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
jlentini on DSKJ8SOYB1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Substance Abuse and Mental Health
Services Administration
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
BILLING CODE P
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel. Contraceptive
Clinical Trials Network.
Date: January 12, 2011.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate concept
review.
Place: National Institutes of Health, 6100
Executive Boulevard, Room 2A01, Rockville,
MD 20852. (Telephone Conference Call).
Contact Person: Sathasiva B. Kandasamy,
PhD, Scientific Review Administrator,
Division of Scientific Review, National
Institute of Child Health and Human
Development, 6100 Executive Boulevard,
Rockville, Md 20892–9304. (301) 435–6680.
skandasa@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment program, National
Institutes of Health, HHS)
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel.
Date: January 10, 2011.
Time: 12:45 p.m. to 3 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6100
Executive Boulevard, Room 2A01, Rockville,
MD 20852. (Telephone Conference).
Contact Person: Sathasiva B. Kandasamy,
PhD, Scientific Review Administrator,
Division of Scientific Review, National
Institute of Child Health and Human
Development, 6100 Executive Boulevard,
Rockville, MD 20892–9304. (301) 435–6680.
skandasa@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: December 27, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–33068 Filed 12–30–10; 8:45 am]
BILLING CODE 4140–01–P
Dated: December 27, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–33067 Filed 12–30–10; 8:45 am]
BILLING CODE 4140–01–P
VerDate Mar<15>2010
15:48 Dec 30, 2010
Jkt 223001
161
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
Current List of Laboratories and
Instrumented Initial Testing Facilities
Which Meet Minimum Standards To
Engage in Urine Drug Testing for
Federal Agencies
AGENCY: Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
SUMMARY: The Department of Health and
Human Services (HHS) notifies Federal
agencies of the Laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently certified
Laboratories and Instrumented Initial
Testing Facilities (IITF) is published in
the Federal Register during the first
week of each month. If any Laboratory/
IITF’s certification is suspended or
revoked, the Laboratory/IITF will be
omitted from subsequent lists until such
time as it is restored to full certification
under the Mandatory Guidelines.
If any Laboratory/IITF has withdrawn
from the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov and https://
www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs.
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 2–
1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs’’, as amended in the
revisions listed above, requires {or set}
strict standards that Laboratories and
E:\FR\FM\03JAN1.SGM
03JAN1
162
Federal Register / Vol. 76, No. 1 / Monday, January 3, 2011 / Notices
Instrumented Initial Testing Facilities
(IITF) must meet in order to conduct
drug and specimen validity tests on
urine specimens for Federal agencies.
To become certified, an applicant
Laboratory/IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a Laboratory/IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and Instrumented Initial
Testing Facilities (IITF) in the applicant
stage of certification are not to be
considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A Laboratory/
IITF must have its letter of certification
from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met
minimum standards.
In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following
Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
jlentini on DSKJ8SOYB1PROD with NOTICES
Instrumented Initial Testing Facilities
(IITF)
None.
Laboratories
ACL Laboratories, 8901 W. Lincoln
Ave., West Allis, WI 53227. 414–328–
7840/800–877–7016. (Formerly:
Bayshore Clinical Laboratory.)
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624.
585–429–2264.
Advanced Toxicology Network, 3560
Air Center Cove, Suite 101, Memphis,
TN 38118. 901–794–5770/888–290–
1150.
Aegis Analytical Laboratories, 345 Hill
Ave., Nashville, TN 37210. 615–255–
2400. (Formerly: Aegis Sciences
Corporation, Aegis Analytical
Laboratories, Inc.)
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053. 504–361–8989/
800–433–3823. (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236. 804–378–9130. (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.)
Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock,
AR 72209–7056. 501–202–2783.
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center.)
VerDate Mar<15>2010
15:48 Dec 30, 2010
Jkt 223001
Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802. 800–
445–6917.
Doctors Laboratory, Inc., 2906 Julia
Drive, Valdosta, GA 31602. 229–671–
2281.
DrugScan, Inc., P.O. Box 2969, 1119
Mearns Road, Warminster, PA 18974.
215–674–9310.
DynaLIFE Dx,* 10150–102 St., Suite
200, Edmonton, Alberta, Canada T5J
5E2. 780–451–3702/800–661–9876.
(Formerly: Dynacare Kasper Medical
Laboratories.)
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655. 662–
236–2609.
Gamma-Dynacare Medical
Laboratories,* A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4. 519–
679–1630.
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040. 713–856–8288/
800–800–2387.
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869. 908–526–2400/800–437–4986.
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709.
919–572–6900/800–833–3984.
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group.)
Laboratory Corporation of America
Holdings, 1120 Main Street,
Southaven, MS 38671. 866–827–8042/
800–233–6339. (Formerly: LabCorp
Occupational Testing Services, Inc.;
MedExpress/National Laboratory
Center.)
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219. 913–888–3927/800–873–8845.
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.)
Maxxam Analytics,* 6740 Campobello
Road, Mississauga, ON, Canada L5N
* The Standards Council of Canada (SCC) voted
to end its Laboratory Accreditation Program for
Substance Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that program were
accredited to conduct forensic urine drug testing as
required by U.S. Department of Transportation
(DOT) regulations. As of that date, the certification
of those accredited Canadian laboratories will
continue under DOT authority. The responsibility
for conducting quarterly performance testing plus
periodic on-site inspections of those LAPSA-
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
2L8. 905–817–5700. (Formerly:
Maxxam Analytics Inc., NOVAMANN
(Ontario), Inc.)
MedTox Laboratories, Inc., 402 W.
County Road D, St. Paul, MN 55112.
651–636–7466/800–832–3244.
MetroLab-Legacy Laboratory Services,
1225 NE 2nd Ave., Portland, OR
97232. 503–413–5295/800–950–5295.
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, MN 55417. 612–725–
2088.
National Toxicology Laboratories, Inc.,
1100 California Ave., Bakersfield, CA
93304. 661–322–4250/800–350–3515.
One Source Toxicology Laboratory, Inc.,
1213 Genoa-Red Bluff, Pasadena, TX
77504. 888–747–3774. (Formerly:
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory.)
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311.
800–328–6942. (Formerly: Centinela
Hospital Airport Toxicology
Laboratory.)
Pathology Associates Medical
Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204. 509–755–8991/
800–541–7891x7.
Phamatech, Inc., 10151 Barnes Canyon
Road, San Diego, CA 92121. 858–643–
5555.
Quest Diagnostics Incorporated, 1777
Montreal Circle, Tucker, GA 30084.
800–729–6432. (Formerly: SmithKline
Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories.)
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403.
610–631–4600/877–642–2216.
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories.)
Quest Diagnostics Incorporated, 8401
Fallbrook Ave., West Hills, CA 91304.
800–877–2520. (Formerly: SmithKline
Beecham Clinical Laboratories.)
S.E.D. Medical Laboratories, 5601 Office
Blvd., Albuquerque, NM 87109. 505–
727–6300/800–999–5227.
accredited laboratories was transferred to the U.S.
HHS, with the HHS’ NLCP contractor continuing to
have an active role in the performance testing and
laboratory inspection processes. Other Canadian
laboratories wishing to be considered for the NLCP
may apply directly to the NLCP contractor just as
U.S. laboratories do.
Upon finding a Canadian laboratory to be
qualified, HHS will recommend that DOT certify
the laboratory (Federal Register, July 16, 1996) as
meeting the minimum standards of the Mandatory
Guidelines published in the Federal Register on
April 30, 2010 (75 FR 22809). After receiving DOT
certification, the laboratory will be included in the
monthly list of HHS-certified laboratories and
participate in the NLCP certification maintenance
program.
E:\FR\FM\03JAN1.SGM
03JAN1
Federal Register / Vol. 76, No. 1 / Monday, January 3, 2011 / Notices
South Bend Medical Foundation, Inc.,
530 N. Lafayette Blvd., South Bend,
IN 46601. 574–234–4176 x1276.
Southwest Laboratories, 4625 E. Cotton
Center Boulevard, Suite 177, Phoenix,
AZ 85040. 602–438–8507/800–279–
0027.
St. Anthony Hospital Toxicology
Laboratory, 1000 N. Lee St.,
Oklahoma City, OK 73101. 405–272–
7052.
STERLING Reference Laboratories, 2617
East L Street, Tacoma, Washington
98421, 800–442–0438.
Toxicology & Drug Monitoring
Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop
70 West, Suite 208, Columbia, MO
65203. 573–882–1273.
Toxicology Testing Service, Inc., 5426
N.W. 79th Ave., Miami, FL 33166.
305–593–2260.
U.S. Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–
5235. 301–677–7085.
Dated: December 15, 2010.
Elaine Parry,
Director, Office of Management, Technology,
and Operations, SAMHSA.
[FR Doc. 2010–32908 Filed 12–30–10; 8:45 am]
BILLING CODE 4160–20–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Agency Information Collection
Activities: CBP Regulations Pertaining
to Customs Brokers
jlentini on DSKJ8SOYB1PROD with NOTICES
AGENCY: U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: 30-Day notice and request for
comments; Extension of an existing
information collection: 1651–0034.
SUMMARY: U.S. Customs and Border
Protection (CBP) of the Department of
Homeland Security will be submitting
the following information collection
request to the Office of Management and
Budget (OMB) for review and approval
in accordance with the Paperwork
Reduction Act: CBP Regulations
Pertaining to Customs Brokers (19 CFR
part 111). This is a proposed extension
of an information collection that was
previously approved. CBP is proposing
that this information collection be
extended with no change to the burden
hours or to the information being
collected. This document is published
to obtain comments from the public and
affected agencies. This proposed
information collection was previously
VerDate Mar<15>2010
15:48 Dec 30, 2010
Jkt 223001
published in the Federal Register (75
FR 67094) on November 1, 2010,
allowing for a 60-day comment period.
This notice allows for an additional 30
days for public comments. This process
is conducted in accordance with 5 CFR
1320.10.
DATES: Written comments should be
received on or before February 2, 2011.
ADDRESSES: Interested persons are
invited to submit written comments on
this proposed information collection to
the Office of Information and Regulatory
Affairs, Office of Management and
Budget. Comments should be addressed
to the OMB Desk Officer for Customs
and Border Protection, Department of
Homeland Security, and sent via
electronic mail to
oira_submission@omb.eop.gov or faxed
to (202) 395–5806.
SUPPLEMENTARY INFORMATION: U.S.
Customs and Border Protection (CBP)
encourages the general public and
affected Federal agencies to submit
written comments and suggestions on
proposed and/or continuing information
collection requests pursuant to the
Paperwork Reduction Act (Pub. L. 104–
13). Your comments should address one
of the following four points:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency/component,
including whether the information will
have practical utility;
(2) Evaluate the accuracy of the
agencies/components estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and
(4) Minimize the burden of the
collections of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
techniques or other forms of
information.
Title: CBP Regulations Pertaining to
Customs Brokers (19 CFR Part 111).
OMB Number: 1651–0034.
Form Numbers: CBP Forms 3124 and
3124E.
Abstract: The information contained
in part 111 of the CBP regulations
governs the licensing and conduct of
customs brokers. Specifically, an
individual who wishes to take the
broker exam would complete CBP Form
3124E, ‘‘Application for Customs Broker
License Exam’’; or to apply for a broker
license, CBP Form 3124, ‘‘Application
for Customs Broker License’’ must be
completed. The procedures to request a
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
163
local or national broker permit can be
found in 19 CFR 111.19, and a triennial
report is required under 19 CFR 111.30.
The information collected from customs
brokers is provided for by 19 U.S.C.
1641. CBP Forms 3124 and 3124E may
be found at https://www.cbp.gov/xp/
cgov/toolbox/forms/. Further
information about the customs broker
exam and how to apply for it may be
found at https://www.cbp.gov/xp/cgov/
trade/trade_programs/broker/
broker_exam/notice_of_exam.xml.
Current Actions: This submission is
being made to extend the expiration
date with no change to the burden hours
or to this collection of information.
Type of Review: Extension (without
change).
Affected Public: Businesses,
Individuals.
CBP Form 3124E, ‘‘Application for
Customs Broker License Exam
Estimated Number of Respondents:
2,300.
Total Number of Estimated Annual
Responses: 2,300.
Estimated Time per Response: 1 hour.
Estimated Total Annual Burden
Hours: 2,300.
Estimated Total Annual Cost to the
Public: $466,000.
CBP Form 3124, ‘‘Application for
Customs Broker License’’
Estimated Number of Respondents:
300.
Total Number of Estimated Annual
Responses: 300.
Estimated Time per Response: 1 hour.
Estimated Total Annual Burden
Hours: 300.
Triennial Report (19 CFR 111.30)
Estimated Number of Respondents:
3,833.
Total Number of Estimated Annual
Responses: 3,833.
Estimated Time per Response: .5
hours.
Estimated Total Annual Burden
Hours: 1,917.
Estimated Total Annual Cost to the
Public: $383,300.
National Broker Permit Application
(19 CFR 111.19)
Estimated Number of Respondents:
500.
Total Number of Estimated Annual
Responses: 500.
Estimated Time per Response: 1 hour.
Estimated Total Annual Burden
Hours: 500.
Estimated Total Annual Cost to the
Public: $112,500.
If additional information is required
contact: Tracey Denning, U.S. Customs
and Border Protection, Regulations and
Rulings, Office of International Trade,
799 9th Street, NW., 5th Floor,
E:\FR\FM\03JAN1.SGM
03JAN1
]]>Agencies
[Federal Register Volume 76, Number 1 (Monday, January 3, 2011)]
[Notices]
[Pages 161-163]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-32908]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of Laboratories and Instrumented Initial Testing
Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing
for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
Federal agencies of the Laboratories and Instrumented Initial Testing
Facilities (IITF) currently certified to meet the standards of the
Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines). The Mandatory Guidelines were first published
in the Federal Register on April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal Register on June 9, 1994 (59 FR
29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and
on April 30, 2010 (75 FR 22809).
A notice listing all currently certified Laboratories and
Instrumented Initial Testing Facilities (IITF) is published in the
Federal Register during the first week of each month. If any
Laboratory/IITF's certification is suspended or revoked, the
Laboratory/IITF will be omitted from subsequent lists until such time
as it is restored to full certification under the Mandatory Guidelines.
If any Laboratory/IITF has withdrawn from the HHS National
Laboratory Certification Program (NLCP) during the past month, it will
be listed at the end and will be omitted from the monthly listing
thereafter.
This notice is also available on the Internet at https://www.workplace.samhsa.gov and https://www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of
Workplace Programs, SAMHSA/CSAP, Room 2-1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).
SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially
developed in accordance with Executive Order 12564 and section 503 of
Public Law 100-71. The ``Mandatory Guidelines for Federal Workplace
Drug Testing Programs'', as amended in the revisions listed above,
requires {or set{time} strict standards that Laboratories and
[[Page 162]]
Instrumented Initial Testing Facilities (IITF) must meet in order to
conduct drug and specimen validity tests on urine specimens for Federal
agencies.
To become certified, an applicant Laboratory/IITF must undergo
three rounds of performance testing plus an on-site inspection. To
maintain that certification, a Laboratory/IITF must participate in a
quarterly performance testing program plus undergo periodic, on-site
inspections.
Laboratories and Instrumented Initial Testing Facilities (IITF) in
the applicant stage of certification are not to be considered as
meeting the minimum requirements described in the HHS Mandatory
Guidelines. A Laboratory/IITF must have its letter of certification
from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met
minimum standards.
In accordance with the Mandatory Guidelines dated November 25, 2008
(73 FR 71858), the following Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the minimum standards to conduct drug
and specimen validity tests on urine specimens:
Instrumented Initial Testing Facilities (IITF)
None.
Laboratories
ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227. 414-328-
7840/800-877-7016. (Formerly: Bayshore Clinical Laboratory.)
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624.
585-429-2264.
Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis,
TN 38118. 901-794-5770/888-290-1150.
Aegis Analytical Laboratories, 345 Hill Ave., Nashville, TN 37210. 615-
255-2400. (Formerly: Aegis Sciences Corporation, Aegis Analytical
Laboratories, Inc.)
Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053. 504-361-
8989/800-433-3823. (Formerly: Kroll Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236.
804-378-9130. (Formerly: Kroll Laboratory Specialists, Inc., Scientific
Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories,
Inc.)
Baptist Medical Center-Toxicology Laboratory, 11401 I-30, Little Rock,
AR 72209-7056. 501-202-2783. (Formerly: Forensic Toxicology Laboratory
Baptist Medical Center.)
Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802. 800-
445-6917.
Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602. 229-
671-2281.
DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA 18974.
215-674-9310.
DynaLIFE Dx,* 10150-102 St., Suite 200, Edmonton, Alberta, Canada T5J
5E2. 780-451-3702/800-661-9876. (Formerly: Dynacare Kasper Medical
Laboratories.)
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655.
662-236-2609.
Gamma-Dynacare Medical Laboratories,* A Division of the Gamma-Dynacare
Laboratory Partnership, 245 Pall Mall Street, London, ONT, Canada N6A
1P4. 519-679-1630.
Laboratory Corporation of America Holdings, 7207 N. Gessner Road,
Houston, TX 77040. 713-856-8288/800-800-2387.
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ
08869. 908-526-2400/800-437-4986. (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709. 919-572-6900/800-833-3984. (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group.)
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671. 866-827-8042/800-233-6339. (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center.)
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS
66219. 913-888-3927/800-873-8845. (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.)
Maxxam Analytics,\*\ 6740 Campobello Road, Mississauga, ON, Canada L5N
2L8.905-817-5700. (Formerly: Maxxam Analytics Inc., NOVAMANN (Ontario),
Inc.)
---------------------------------------------------------------------------
* The Standards Council of Canada (SCC) voted to end its
Laboratory Accreditation Program for Substance Abuse (LAPSA)
effective May 12, 1998. Laboratories certified through that program
were accredited to conduct forensic urine drug testing as required
by U.S. Department of Transportation (DOT) regulations. As of that
date, the certification of those accredited Canadian laboratories
will continue under DOT authority. The responsibility for conducting
quarterly performance testing plus periodic on-site inspections of
those LAPSA-accredited laboratories was transferred to the U.S. HHS,
with the HHS' NLCP contractor continuing to have an active role in
the performance testing and laboratory inspection processes. Other
Canadian laboratories wishing to be considered for the NLCP may
apply directly to the NLCP contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (Federal Register, July
16, 1996) as meeting the minimum standards of the Mandatory
Guidelines published in the Federal Register on April 30, 2010 (75
FR 22809). After receiving DOT certification, the laboratory will be
included in the monthly list of HHS-certified laboratories and
participate in the NLCP certification maintenance program.
---------------------------------------------------------------------------
MedTox Laboratories, Inc., 402 W. County Road D,St. Paul, MN 55112.
651-636-7466/800-832-3244.
MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR
97232. 503-413-5295/800-950-5295.
Minneapolis Veterans Affairs Medical Center,Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417. 612-725-2088.
National Toxicology Laboratories, Inc., 1100 California Ave.,
Bakersfield, CA 93304. 661-322-4250/800-350-3515.
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena,
TX 77504. 888-747-3774. (Formerly: University of Texas Medical Branch,
Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory.)
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311. 800-328-6942.(Formerly: Centinela Hospital Airport Toxicology
Laboratory.)
Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane,
WA 99204. 509-755-8991/800-541-7891x7.
Phamatech, Inc., 10151 Barnes Canyon Road,San Diego, CA 92121. 858-643-
5555.
Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084.
800-729-6432.(Formerly: SmithKline Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories.)
Quest Diagnostics Incorporated, 400 Egypt Road,Norristown, PA 19403.
610-631-4600/877-642-2216. (Formerly: SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science Laboratories.)
Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA
91304. 800-877-2520.(Formerly: SmithKline Beecham Clinical
Laboratories.)
S.E.D. Medical Laboratories, 5601 Office Blvd.,Albuquerque, NM 87109.
505-727-6300/800-999-5227.
[[Page 163]]
South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South
Bend, IN 46601. 574-234-4176 x1276.
Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177,
Phoenix, AZ 85040. 602-438-8507/800-279-0027.
St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma
City, OK 73101. 405-272-7052.
STERLING Reference Laboratories, 2617 East L Street, Tacoma, Washington
98421, 800-442-0438.
Toxicology & Drug Monitoring Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO
65203. 573-882-1273.
Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL 33166.
305-593-2260.
U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755-5235. 301-677-7085.
Dated: December 15, 2010.
Elaine Parry,
Director, Office of Management, Technology, and Operations, SAMHSA.
[FR Doc. 2010-32908 Filed 12-30-10; 8:45 am]
BILLING CODE 4160-20-P
